Zacks Research Forecasts Reduced Earnings for Avanos Medical

Avanos Medical, Inc. (NYSE:AVNS) – Equities researchers at Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for shares of Avanos Medical in a report released on Wednesday, November 20th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.41 for the quarter, down from their prior forecast of $0.57. The consensus estimate for Avanos Medical’s current full-year earnings is $1.32 per share. Zacks Research also issued estimates for Avanos Medical’s Q4 2025 earnings at $0.53 EPS and FY2025 earnings at $1.64 EPS.

Separately, StockNews.com lowered Avanos Medical from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 3rd.

Avanos Medical Stock Performance

AVNS opened at $19.16 on Monday. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12. Avanos Medical has a 12-month low of $17.39 and a 12-month high of $25.36. The firm has a 50 day moving average of $21.64 and a two-hundred day moving average of $21.56. The firm has a market capitalization of $880.59 million, a PE ratio of 56.97 and a beta of 0.92.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Paradice Investment Management LLC increased its stake in Avanos Medical by 5.4% during the 2nd quarter. Paradice Investment Management LLC now owns 1,344,949 shares of the company’s stock worth $26,791,000 after buying an additional 69,389 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Avanos Medical by 1.5% during the third quarter. Geode Capital Management LLC now owns 1,054,162 shares of the company’s stock worth $25,337,000 after purchasing an additional 16,065 shares in the last quarter. Foundry Partners LLC raised its stake in Avanos Medical by 1.1% in the 3rd quarter. Foundry Partners LLC now owns 163,030 shares of the company’s stock valued at $3,918,000 after purchasing an additional 1,800 shares during the last quarter. AQR Capital Management LLC boosted its stake in Avanos Medical by 21.0% during the 2nd quarter. AQR Capital Management LLC now owns 146,983 shares of the company’s stock worth $2,875,000 after purchasing an additional 25,467 shares during the last quarter. Finally, FMR LLC grew its holdings in shares of Avanos Medical by 34.6% during the third quarter. FMR LLC now owns 133,844 shares of the company’s stock worth $3,216,000 after buying an additional 34,421 shares in the last quarter. Hedge funds and other institutional investors own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.